Healthcare / BiotechnologyNasdaqGS
$593.30
-7.36 (-1.23%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 22% · confianza 25%
FCF escenarios
weak_data · normalized FCF $3.7B · quality 84.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
61/100
B
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$62.2B
P/E
14.5x
↓EV/EBITDA
11.0x
↓ROE
14.4%
↑Gross Margin
85.4%
↑Debt/Equity
0.09
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2008–2025 · 17 años de histórico normalizado
Revenue CAGR
+27.3%
FCF CAGR
—
FCF margin
26.3%
FCF / Net income
0.84x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $14.34B · net income $4.50B · FCF $3.77B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||||||||
| Revenue | $14.34B | $14.34B | $14.20B | $13.12B | $12.17B | $16.07B | $8.50B | $6.56B | $5.15B | $5.87B | $4.86B | $4.10B | $2.82B | $2.10B | $1.38B | $445.8M | $459.1M | $379.3M | $238.5M |
| Net Income | $4.50B | $4.50B | $4.41B | $3.95B | $4.34B | $8.08B | $3.51B | $2.12B | $2.44B | $1.20B | $895.5M | $636.1M | $338.1M | $413.7M | $750.3M | $-221.8M | $-104.5M | $-67.8M | $-79.1M |
| EBITDA | $5.82B | $5.82B | $5.32B | $4.69B | $5.26B | $9.23B | $3.81B | $2.42B | $2.68B | $2.23B | $1.44B | $1.33B | $876.6M | $784.3M | $494.7M | $-174.1M | $-77.8M | $-59.9M | $-75.0M |
| EPS | 41.48 | 41.48 | 38.34 | 34.77 | 38.22 | 71.97 | 30.52 | 18.46 | 21.29 | 10.34 | 7.70 | 5.52 | 2.98 | 3.72 | 6.75 | -2.45 | -1.26 | — | — |
| Gross Margin | 85.4% | 85.4% | 86.1% | 86.2% | 87.2% | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | 25.8% | 25.8% | 28.1% | 30.9% | 38.9% | 55.7% | 42.1% | 33.7% | 49.3% | 35.4% | 27.4% | 30.5% | 29.2% | 35.3% | 33.2% | -46.0% | -21.2% | -19.5% | -36.2% |
| Net Margin | 31.4% | 31.4% | 31.1% | 30.1% | 35.6% | 50.2% | 41.3% | 32.3% | 47.5% | 20.4% | 18.4% | 15.5% | 12.0% | 19.7% | 54.4% | -49.7% | -22.8% | -17.9% | -33.2% |
| Balance Sheet | |||||||||||||||||||
| Debt/Equity | 0.09 | 0.09 | 0.09 | 0.10 | 0.12 | 0.11 | 0.18 | 0.00 | — | — | — | — | — | — | — | — | — | — | — |
| Current Ratio | 3.56 | 3.56 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | |||||||||||||||||||
| Free Cash Flow | $3.77B | $3.77B | $3.54B | $3.67B | $3.40B | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Returns | |||||||||||||||||||
| ROE | 14.4% | 14.4% | 15.0% | 15.2% | 19.1% | 43.0% | 31.9% | 19.1% | 27.9% | 19.5% | 20.1% | 17.4% | 13.3% | 21.1% | 59.7% | -45.7% | -19.8% | -17.1% | -18.8% |
| Valuation | |||||||||||||||||||
| P/E | 14.48 | 14.48 | 18.73 | 26.26 | 19.29 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| EV/EBITDA | 11.00 | 11.00 | 15.58 | 22.12 | 15.83 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| P/B | 2.06 | 2.06 | 2.82 | 4.00 | 3.69 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | |||||||||||||||||||
| Revenue Growth | 1.0% | 1.0% | 8.3% | 7.8% | — | 89.1% | 29.6% | 27.4% | -12.4% | 20.8% | 18.4% | 45.5% | 34.0% | 52.7% | 209.2% | -2.9% | 21.0% | 59.1% | — |
| EPS Growth | 8.2% | 8.2% | 10.3% | -9.0% | — | 135.8% | 65.3% | -13.3% | 105.9% | 34.3% | 39.5% | 85.2% | -19.9% | -44.9% | 375.5% | -94.4% | — | — | — |
| Dividend Yield | 0.6% | 0.6% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
8.3%
EPS terminal req.
$52.65
Spread vs growth
-0.1%
5Y implied EPS CAGR
9.0%
EPS terminal req.
$63.70
Spread vs growth
-0.8%
10Y implied EPS CAGR
9.5%
EPS terminal req.
$102.59
Spread vs growth
-1.3%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+21.5%
Start / end P/E
12.8x → 14.3x
EPS bridge
38.34 → 41.48
Residual
+1.0%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.